Advaxis Listeria live vaccine ‘for prostate cancer is clinically

Chandan Guha at the Albert Einstein College of Medicine and Montefiore Medical Center to develop ADXS31-142 in human patients. After the completion of production tests, the company plans to conduct a Phase 1 study with Dr. Guha.Advaxis vaccine for prostate cancer generates a strong immune response that attacks and kills cells that secrete prostate specific antigen , a commonly used clinical indicator of prostate cancer. The company has published preclinical work demonstrates the ability of ADXS31-142, a Listeria live vaccine against PSA :. 96 – 103).

With regard to the initiative Advaxis prostate, Dr. John Rothman, Executive Vice President of Operations and Science said: Prostate cancer is an excellent target for immunotherapy. We believe that our approach compared with treatment Provenge recently approved.

reuteri obtained from pigs in a high-level design and also provided a full statement. The annotation is needed to identify the genes that relate to what works in the sequence. Comparisons between different strains of L.

reuteri, which have already been made available in major international sequence databases identified a set of genes unique to this particular strain.